|
Press Releases |
|
|
|
Wednesday, January 3, 2024 |
|
冠科美博在中国完成复发或难治性急性髓细胞白血病uproleselan药物的三期临床桥接研究入组 |
冠科美博(纳斯达克股票代码:APLM)(以下简称“冠科美博”或“公司”),是一家专注于开发治疗复发或难治的癌症药物的生物制药公司,今天宣布在中国已完成了对复发/难治性急性髓细胞性白血病(R/R AML)患者进行的临床三期桥接研究的入组工作。 more info >> |
|
冠科美博在中國完成復發或難治性急性髓細胞白血病uproleselan藥物的三期臨床橋接研究入組 |
冠科美博(納斯達克股票代碼:APLM)(以下簡稱“冠科美博”或“公司”),是一家專注於開發治療復發或難治的癌症藥物的生物製藥公司,今天宣佈在中國已完成了對復發/難治性急性髓細胞性白血病(R/R AML)患者進行的臨床三期橋接研究的入組工作。 more info >> |
|
Thursday, March 30, 2023 |
|
冠科美博(Apollomics Inc.)宣佈完成和SPAC Maxpro合併,並在納斯達克上市 |
冠科美博 (Apollomics Inc.),一家臨床階段的開發多個抗腫瘤候選藥物以解決難以治療和治療耐藥的癌症的創新型生物製藥公司,今天宣佈完成與Maxpro Capital Acquisition Corp.(“Maxpro”,納斯達克股票代碼:JMAC)的業務合併。 more info >> |
|
冠科美博(Apollomics Inc.)宣布完成和SPAC Maxpro合并,并在纳斯达克上市 |
冠科美博 (Apollomics Inc.),一家临床阶段的开发多个抗肿瘤候选药物以解决难以治疗和治疗耐药的癌症的创新型生物制药公司,今天宣布完成与Maxpro Capital Acquisition Corp.(“Maxpro”,纳斯达克股票代码:JMAC)的业务合并。 more info >> |
|
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq |
Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. ("Maxpro", Nasdaq: JMAC). more info >> |
|
Tuesday, July 26, 2022 |
|
冠科美博 (Apollomics Inc.) 扩充其领导团队,任命 Jane Wang 博士担任首席科学官一职 |
冠科美博 (Apollomics Inc.) 是一家致力于发现和开发单药及联合肿瘤疗法的创新生物制药公司,于今天宣布任命 Jane Wang 博士担任首席科学官一职。 more info >> |
|
冠科美博 (Apollomics Inc.) 擴充其領導團隊,任命 Jane Wang 博士擔任首席科學官一職 |
冠科美博 (Apollomics Inc.) 是一家致力於發現和開發單藥及聯合腫瘤療法的創新生物製藥公司,於今天宣佈任命 Jane Wang 博士擔任首席科學官一職。 more info >> |
|
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer |
Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery pipeline for the Company. She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer. more info >> |
|
Wednesday, January 12, 2022 |
|
冠科美博 (Apollomics Inc.) 将于 2022 年 1 月 26-27 日(周三、周四)举办线上投资者活动 |
冠科美博(Apollomics Inc.),一家致力于发现和开发单药及组合肿瘤疗法的创新生物制药公司,今日宣布,管理团队将为来自美国和中国的参会者举办两场网络直播 more info >> |
|
冠科美博 (Apollomics Inc.) 將於 2022 年 1 月 26-27 日(週三、週四)舉辦線上投資者活動 |
冠科美博(Apollomics Inc.),一家致力於發現和開發單藥及組合腫瘤療法的創新生物製藥公司,今日宣佈,管理團隊將為來自美國和中國的參會者舉辦兩場網路直播 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 22, 2024 22:42 JST
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
达丰设备服务有限公司 公布2024/25中期业绩
Nov 22, 2024 19:35 HKT/SGT
|
|
|
達豐設備服務有限公司 公佈2024/25中期業績
Nov 22, 2024 19:18 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 22, 2024 14:42 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 22, 2024 14:41 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 12:00: JST
|
|
|
Daeshin MC Co., Ltd.は、産業現場から公共施設まで快適な室内環境を作り出すクリーンソリューションを発表
Nov 22, 2024 12:00: JST
|
|
|
三菱重工、新たな防衛輸送用「機動舟艇」に搭載するウォータージェット推進装置の供給へ
Nov 22, 2024 11:45: JST
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2%
Nov 22, 2024 10:00 HKT/SGT
|
|
|
アレス・マネジメント、東京オフィス開設でアジア事業を拡充
Nov 22, 2024 09:00: JST
|
|
|
|
More News >> |
|
|
|
|
|